Key points – Pembrolizumab was first shown to be clinically active in CLL patients with Richter Transformation. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select Richter Transformation patients for PD-1 blockade.
Home / Resource Library / Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL